

Internal Notes:

Processed by:\_\_\_\_\_\_\_\_\_\_\_

Assigned on:\_\_\_\_\_\_\_\_\_\_\_\_

Shipped/picked up on:\_\_\_\_\_\_\_\_\_\_\_\_\_

**Gene Transfer, Targeting and Therapeutics Facility**

# Stock Reporter Viral Vector Request Form

 **Email completed form to GT3@salk.edu**

## Billing Information. Order#:

|  |  |
| --- | --- |
| **Principal Investigator (PI):**  | **Requesting Investigator / Lab contact:** |
| **Order Date:** | **Contact Phone:** |
| **Salk Users. Fund number:** | **Contact E-mail:** |
| **External Users. PO Number** **(credit cards are NOT accepted):** |  |
| **Billing address:** | **Shipping address:** |

**Top of Form**

**Bottom of Form**

**rAAV [50ul / aliquot] AddGene Titer[vg/mL] Requested**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| AAV1–CMV-eGFP |  |  | 5.13E+12 |  |  |
| AAV2-CMV-eGFP  |  |  | 1.20E+11 |  |  |
| AAV5-CMV-eGFP  |  |  | 7.63E+10 |  |  |
| AAV6-CMV-eGFP  |  |  | 1.90E+11 |  |  |
| AAV8-CMV-eGFP |  |  | 1.48E+12 |  |  |
| AAV9-CMV-eGFP  |  |  | 9.55E+11 |  |  |
| AAVDJ-CMV-eGFP |  |  | 5.30E+12 |  |  |
| AAVrh10-CMV-eGFP |  |  | 1.36E+13 |  |  |
| AAV1-Hsyn-dsRed  |  |  | 4.00E+13 |  |  |
| AAV2-Hsyn-dsRed  |  |  | 9.10E+12 |  |  |
| AAV1-CMV-dsRed  |  |  | 1.80E+10 |  |  |
| AAV2-CMV-dsRed  |  |  | 3.90E+13 |  |  |
| AAV8-CAG-LssmOrange |  |  | 2.67E+11 |  |  |
| AAV8-CAG-iRFP |  |  | 2.46E+11 |  |  |
| AAV8-CAG-mRuby2 |  |  | 3.76E+11 |  |  |
| AAV8-CAG-PSmOrange2 |  |  | 8.52E+12 |  |  |
| AAV8-CAG-mNeptuneN2 |  |  | 1.27E+13 |  |  |
| AAV2-CAG-mCherry-p2A-Cre |  |  | 2.71E+12 |  |  |
| AAVLK03-RSV-eGFP |  |  | 1.29E+13 |  |  |
| **Cre** |  |  |  |  |  |
| AAV2-CAG-Cre-eGFP  |  |  | 5.90E+13 |  |  |
| AAVDJ-CAG-Cre-GFP |  |  | 2.10E+12 |  |  |
| AAVDJ-CMV-Cre |  |  | 1.00E+11 |  |  |
| **DIO** |  |  |  |  |  |
| AAV1-EF1a-DIO-HTB  | 44187 |  | 6.40E+11 |  |  |
| AAV2-EF1a-DIO-HTB  | 44187 |  | 1.20E+11 |  |  |
| AAV8-EF1a-DIO-HTB  | 44187 |  | 7.00E+11 |  |  |
| AAVDJ-EF1a-DIO-HTB  | 44187 |  | 2.20E+11 |  |  |
| AAV1-EF1a-DIO-HB  | 37452 |  | 2.11E+11 |  |  |
| AAV2-EF1a-DIO-HB  | 37452 |  | 1.30E+11 |  |  |
| AAV8-EF1a-DIO-HB  | 37452 |  | 6.20E+11 |  |  |
| AAVDJ-EF1a-DIO-HB  | 37452 |  | 2.45E+11 |  |  |
| AAVDJ-Syn1-DIO-eGFP |  |  | 3.56E+13 |  |  |
| **FLEX** |  |  |  |  |  |
| AAV1-EF1a-FLEX-GT | 26198 |  | 1.65E+13 |  |  |
| AAV2-EF1a-FLEX-GT | 26198 |  | 4.41E+12 |  |  |
| AAV8-EF1a-FLEX-GT | 26198 |  | 3.20E+13 |  |  |
| AAVDJ-EF1a-FLEX-GT | 26198 |  | 1.22E+13 |  |  |
| AAV1-EF1a-FLEX-GTB | 26197 |  | 4.72E+12 |  |  |
| AAV2-EF1a-FLEX-GTB | 26197 |  | 4.52E+12 |  |  |
| AAV2-EF1a-FLEX-GTB  | 26197 |  | 1.70E+11 |  |  |
| AAV8-EF1a-FLEX-GTB | 26197 |  | 7.76E+12 |  |  |
| AAVDJ-EF1a-FLEX-GTB | 26197 |  | 2.40E+12 |  |  |
| AAV8-FLEX-GFP  | 28304 |  | 1.83E+11 |  |  |
| AAV8-FLEX-ArchT-GFP | 28307 |  | 7.05E+10 |  |  |
| AAV8-FLEX-ArchT-tdTomato  | 28305 |  | 2.66E+11 |  |  |
| AAVDJ-FLEX-ArchT-GFP | 28307 |  | 3.31E+11 |  |  |
| AAVDJ-FLEX-ArchT-td-Tomato | 28305 |  | 4.13E+11 |  |  |
| AAV8-CAG-Arch-GFP | 37810 |  | 1.54E+11 |  |  |
| AAVDJ-CAG-Arch-GFP | 37810 |  | 2.30E+11 |  |  |
| AAV8-CAG-ArchT-Td-Tomato | 29778 |  | 1.81E+11 |  |  |
| AAVDJ-CAG-ArchT-Td-Tomato | 29778 |  | 1.11E+11 |  |  |
| AAVDJ-ChETA-eYFP |  |  | 1.80E+12 |  |  |
|  |  |  |  |  |  |
| Crude AAVDJ-CMV-eGFP |  |  | 6.32E+12 |  |  |
| Crude AAV1-syn-ChR2(H134R)-eYFP  | 26973 |  | 1.16E+11 |  |  |
| Crude AAV2-syn-ChR2(H134R)-eYFP | 26973 |  | 2.95E+10 |  |  |
| Crude AAV6-syn-ChR2(H134R)-eYFP | 26973 |  | 6.70E+10 |  |  |
| **From Deisseroth Lab:** |  |  |  |  |  |
| AAV1-CaMKIIa-EYFP **\*KD** |  |  | 1.06E+12 |  |  |
| AAV1-CaMKIIa-mCherry **\*KD** |  |  | 3.78E+12 |  |  |

\*KD – requires MTA from Karl Deisseroth, Stanford - deissero@stanford.edu

|  |  |  |
| --- | --- | --- |
| AAV Serotype Kit. CAG-eGFP. Crude. Contains 100ul of: AAV1, 2, 3, 4, 5, 6, 8, 9, 9bd1, rh10, 7m8, 2i8, DJ, LK01, LK02, LK03, LK19, + negative control |  |  |

**Lentivirus [10ul / aliquot] AddGene Titer [TU/mL] # Requested**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| LV-SIN-CMV-eGFP |  |  | 2.10E+11 |  |  |
| LV-SIN-Ubi-iCre-mCherry  |  |  | 2.50E+11 |  |  |
| LV-OKMS |  |  | 4.20E+10 |  |  |
| LV-pBOB-synP-HTB | 30195 |  | 5.03E+10 |  |  |
| LV-pBOB-synP-HT | 30456 |  | 7.35E+10 |  |  |
| LV-CaMKIIa-C1V1-EYFP **\*KD** |  |  | 2.85E+09 |  |  |
| LV-CaMKIIa-C1V1-TS-EYFP **\*KD** |  |  | 2.32E+08 |  |  |
| LV-pRRL-hPGK-mCherry-WPRE |  |  | 1.08E+11 |  |  |
| LV-pRRL-hPGK-eGFP-WPRE |  |  | 1.05E+11 |  |  |
| LV-pRRL-hPGK-tdTomato-WPRE |  |  | 1.43E+11 |  |  |

\*KD – requires MTA from Karl Deisseroth, Stanford - deissero@stanford.edu

**Retrovirus [10ul / aliquot] Titer # Requested**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| RV-CAG-eGFP |  | 1.8e11 TU/ml QPCR5.0e8 TU/mL FACS |  |  |
| Large RV-OSKM Reprogramming Kit |  |  |  |  |
| Small RV-OSKM Reprogramming Kit |  |  |  |  |

**Rabies [10ul / aliquot] AddGene Titer [TU/mL] Requested**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| G-deleted Rabies-eGFP | 32635 |  | 2.20E+09 |  |  |
| G-deleted Rabies-mCherry  | 32636 |  | 4.50E+09 |  |  |
| G-Deleted Rabies-ChR2-mCherry  | 32646 |  | 5.30E+09 |  |  |
| G-Deleted Rabies GCaMP3-dsRedXpress  | 32645 |  | 5.20E+09 |  |  |
| G-Deleted Rabies eGFP-Er(T2)CreEr(T2) | 32649 |  | 5.50E+09 |  |  |
| G-Deleted Rabies eGFP-rtTA  | 32648 |  | 6.90E+09 |  |  |
| G-Deleted Rabies BFP | 32639 |  | 1.70E+09 |  |  |
| G-Deleted Rabies FLPo-dsRedXpress  | 32650 |  | 1.24E+09 |  |  |
| G-Deleted Rabies AlstR-GFP  | 32647 |  | 9.30E+09 |  |  |
| G-Deleted Rabies dsRedXpress  | 32638 |  | 5.42E+09 |  |  |
| G-Deleted Rabies mCherry-Myc  | 32637 |  | 5.20E+09 |  |  |
| G-Deleted Rabies GCaMP3 | 32644 |  | 3.40E+09 |  |  |
| G-Deleted Rabies-GCamp6-dsRed |  |  | 5.20E+08 |  |  |
| EnvA G-deleted Rabies-eGFP  |  |  | 4.30E+08 |  |  |
| EnvA G-deleted Rabies-mCherry |  |  | 1.30E+09 |  |  |
| EnvA G-deleted Rabies-ChR2-mCherry  |  |  | 2.20E+07 |  |  |
| EnvA G-Deleted Rabies GCaMP3-dsRedXpress  |  |  | 2.70E+07 |  |  |
| EnvA G-Deleted Rabies eGFP-Er(T2)CreEr(T2) |  |  | 2.50E+08 |  |  |
| EnvA G-Deleted Rabies eGFP-rtTA |  |  | 8.50E+07 |  |  |
| EnvA G-Deleted Rabies BFP |  |  | 1.83E+07 |  |  |
| EnvA G-Deleted Rabies FLPo-dsRedXpress |  |  | 8.55E+06 |  |  |
| EnvA G-Deleted Rabies AlstR-GFP |  |  | 2.32E+08 |  |  |
| EnvA G-Deleted Rabies-GCamp6-dsRed |  |  | 7.53E+08 |  |  |

**VSV [10ul / aliquot] Titer [TU/mL # Requested**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Single Cycle Variants |  |  |  |  |
| G-Deleted VSV-eGFP  |  |  |  |  |
| G-Deleted VSV-mCherry |  |  |  |  |
| G-Deleted VSV-Venus |  |  |  |  |
| G-Deleted VSV-tdTomato |  |  |  |  |
| EnvA G-Deleted VSV-tdTomato |  |  |  |  |
|  |  |  |  |  |
| Replication competent variants |  |  |  |  |
| EnvA VSV-eGFP (contains EnvA/RABVG fusion & eGFP in viral genome) |  |  |  |  |
| RABV-G VSV-eGFP (contains rabies glycoprotein and eGFP in viral genome) |  | 4.04E+9  |  |  |
| LCMV-G VSV-eGFP (contains lymphocytic choriomeningitis glycoprotein and eGFP in viral genome) |  | 7.20E+8  |  |  |
| VSV-G VSV-Venus 1 (a plaque purified isolate, number 14)  |  | 4.60E+8  |  |  |
| VSV-G VSV-Venus 2 (a plaque purified isolate, number 21) |  | 8.22E+9  |  |  |

**Adeno [50ul / aliquot] Info # Requested**

|  |  |  |  |
| --- | --- | --- | --- |
| Ad5-CMV-tdTomato |  |  |  |
| Ad5-CMV-Cre |  |  |  |
| Ad5-CMV-eGFP |  |  |  |
| Ad5-EF1a-tdTomato |  |  |  |
| Ad5/34-CMV-tdTomato | Ad5/knob 34 |  |  |
| Ad5-EF1-Luc-eGFP |  |  |  |
| Ad5/35-CMV-eGFP | E1- / 1st Generation |  |  |
| Ad35-CMV-YFP | E1a+ / Rep Competent |  |  |

TERMS AND CONDITIONS OF SALE AND LIMITED USE AGREEMENT BETWEEN THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (“SALK”) AND RECIPIENT OF BIOLOGICAL MATERIALS

Biological materials to which this Limited Use Agreement applies:

**Lentiviral vectors, Retroviral vectors, Adeno-associated viral vectors and Adenoviral vectors, Herpes Simplex viral vectors, Rabies viral vectors and Vesicular Stomatitis viral vectors generated by the Salk Institute Gene Transfer, Targeting and Therapeutics Core Facility (GT3).**

- and any progeny or unmodified derivatives thereof and any related information or material supplied in connection therewith by Salk (the "Biological Materials"). Salk retains ownership of Biological Materials, including any Biological Materials contained or incorporated in modifications. Ownership of modifications and derivatives of Biological Materials will be determined in good faith by the parties hereto depending upon the parties' relative contributions to the creation of said modifications and derivatives.

We are pleased to provide the Biological Materials, from the GT3 Core Facilityof Salk, subject to terms contained herein.

1. Your institution and your investigator WILL:
	1. Use the Materials only for academic research.
	2. Use them safely and in compliance with all laws, regulations, and NIH guidelines.
	3. Be responsible for any injury or damages that your use may cause.
	4. Acknowledge Salk’s investigator as the source of the Materials in publications.
	5. Return or destroy the Materials when no longer needed or on Salk’s request.
	6. Determine with Salk in good faith the ownership of modifications and derivatives.
	7. Pay Salk for actual shipping costs or provide Federal Express account number.
2. Your institution and your investigator WILL NOT:
	1. Distribute the Materials to anyone else, even within the institution, without Salk’s consent.
	2. Administer the Materials to humans, or use them in human diagnosis or treatment.
	3. Use the Materials for commercial purposes, e.g., drug screening, product testing, product production or product development, sale, lease, license, or transfer to a for-profit entity.
	4. Have a license to Salk intellectual property beyond use of Materials in academic research.
	5. Assign this MTA to any other party.
3. Legal Limitations:
	1. SALK PROVIDES THE MATERIALS “AS IS,” AND SALK DISCLAIMS AND PROVIDES NO REPRESENTATION OR WARRANTY WHATSOEVER.
	2. WITHOUT LIMITING (a) ABOVE, SALK DISCLAIMS AND PROVIDES NO WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, EXPRESS OR IMPLIED.
	3. WITHOUT LIMITING (a) ABOVE, SALK DISCLAIMS AND PROVIDES NO REPRESENTATION OR WARRANTY THAT USE OF THE MATERIALS WILL NOT INFRINGE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.
	4. This is the whole agreement, and it can only be amended in writing.